- Home
- BEAM vs AKRO Comparison
BEAM vs AKRO Comparison
Compare BEAM & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- AKRO
- Stock Information
- Founded
- BEAM 2017
- AKRO 2017
- Country
- BEAM United States
- AKRO United States
- Employees
- BEAM N/A
- AKRO N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- BEAM Health Care
- AKRO Health Care
- Exchange
- BEAM Nasdaq
- AKRO Nasdaq
- Market Cap
- BEAM 1.9B
- AKRO 2.0B
- IPO Year
- BEAM 2020
- AKRO 2019
- Fundamental
- Price
- BEAM $24.70
- AKRO $28.08
- Analyst Decision
- BEAM Buy
- AKRO Strong Buy
- Analyst Count
- BEAM 10
- AKRO 8
- Target Price
- BEAM $47.67
- AKRO $46.83
- AVG Volume (30 Days)
- BEAM 1.1M
- AKRO 594.3K
- Earning Date
- BEAM 02-25-2025
- AKRO 02-27-2025
- Dividend Yield
- BEAM N/A
- AKRO N/A
- EPS Growth
- BEAM N/A
- AKRO N/A
- EPS
- BEAM N/A
- AKRO N/A
- Revenue
- BEAM $349,643,000.00
- AKRO N/A
- Revenue This Year
- BEAM N/A
- AKRO N/A
- Revenue Next Year
- BEAM $10.82
- AKRO N/A
- P/E Ratio
- BEAM N/A
- AKRO N/A
- Revenue Growth
- BEAM 328.73
- AKRO N/A
- 52 Week Low
- BEAM $20.84
- AKRO $15.32
- 52 Week High
- BEAM $49.50
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- BEAM 41.30
- AKRO 41.87
- Support Level
- BEAM $24.96
- AKRO $27.45
- Resistance Level
- BEAM $29.52
- AKRO $28.76
- Average True Range (ATR)
- BEAM 1.64
- AKRO 1.49
- MACD
- BEAM -0.51
- AKRO -0.12
- Stochastic Oscillator
- BEAM 9.71
- AKRO 17.98
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.